Please ensure Javascript is enabled for purposes of website accessibility

Moderna Pulling Back on Coronavirus Vaccine Trial Enrollment to Get More Minority Patients Involved

By Eric Volkman – Sep 4, 2020 at 6:42PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Nearly 70% of those enrolled in the crucial phase 3 study so far are Caucasian.

A world eager for progress on vaccines to guard against the SARS-CoV-2 coronavirus and/or COVID-19 might have to wait a bit longer for a breakthrough. The CEO of Moderna (MRNA -0.23%), the developer of what many experts consider the leading vaccine candidate, said Friday that his company is slowing enrollment in its crucial phase 3 clinical trial.

The reason is that Moderna wants more individuals from minority groups to participate in the study, said Moderna CEO Stephane Bancel in an interview with CNBC. "We want to ensure we have data for all the people who could benefit and be protected," he said.

Child getting a jab from a medical professional.

Image source: Getty Images.

Research shows that, due to a variety of societal and medical factors, minorities are more at risk of contracting and dying from COVID-19. But it isn't proving easy for the company to get people from those communities to sign up for the research.

As of Aug. 28, Moderna had recruited 17,458 individuals for its late-stage trial out of its goal of 30,000 total. Of those enrolled so far, 68% are white, 20% are classified Hispanic or Latino, while the black or African-American and Asian categories are in the single digits, at a respective 7% and 3%. The remaining 2% are "other or unknown." It wasn't immediately clear what its desired levels were for the minority groups.

Moderna's vaccine candidate, mRNA-1273, has been developed relatively quickly. It's one of only several vaccine candidates that has advanced to a phase 3 clinical trial.

On Friday, Moderna's shares sank by almost 3.5%, a steeper fall than that of the S&P 500 index on the day.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna Inc. Stock Quote
Moderna Inc.
$176.40 (-0.23%) $0.41

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.